i
Licensure of a Haemophilus influenzae type b (Hib) Vaccine (Hiberix) and updated recommendations for use of Hib vaccine
-
September 18, 2009
-
Source: MMWR. Morbidity and mortality weekly report. 2009; 58(36):1008-9.
[HTM]
Details:
-
Alternative Title:MMWR. Morbidity and mortality weekly report
-
Description:On August 19, 2009, the Food and Drug Administration (FDA) licensed Hiberix (GlaxoSmithKline Biologicals, Rixensart, Belgium), a Haemophilus influenzae type b (Hib) conjugate vaccine composed of H. influenzae type b capsular polysaccharide (polyribosyl-ribitol-phosphate [PRP]) conjugated to inactivated tetanus toxoid (PRP-T). Hiberix is licensed for use as the booster (final) dose of the Hib vaccine series for children aged 15 months through 4 years (before the 5th birthday) who have received previously the primary series of Hib vaccination (consisting of 2 or 3 doses, depending on the formulation) (1). The Advisory Committee on Immunization Practices (ACIP) recommends Hib booster vaccination for children at ages 12 through 15 months; however, because of the recent shortage of Hib vaccines, many children have deferred the booster dose and therefore require catch-up vaccination (2). This report summarizes the indications for Hiberix use and provides guidance on Hib booster dose administration based on increasing vaccine supplies. Vaccination recommendations in this report update the previous advisory on Hib booster administration (June 26, 2009) (2), which advised that children with deferred booster doses receive it at the next regularly scheduled visit. Vaccination providers are now recommended to begin recall of children in need of the booster dose when feasible and monovalent Hib vaccine supply in the office is adequate.
-
Subjects:
-
Source:
-
Pubmed ID:19763078
-
Document Type:
-
Name as Subject:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
-
File Type:
